Associate Professor of Pharmacology
Affiliate Member, UH Center for Nuclear Receptors
557A Science and Research Building 2
Houston, TX 77204-5037
Ph.D., Neuroscience, Loyola University Chicago, Chicago, IL
Postdoctoral fellow, The Mayo Clinic, Jacksonville, FL
Many neurodegenerative diseases, including Huntington's, Parkinson's, and Alzheimer's diseases, in human patients are both poorly understood and untreatable. In order to develop a deeper understanding of these disorders, a unifying theme in our lab is the study of mechanisms by which protein misfolding in the central nervous system leads to severe brain degeneration.
Our research suggests that the manipulation of protein quality control systems, including the ubiquitin-proteasome system, the autophagic pathway, and heat-shock proteins may all exert dramatic effects on the development of pathology in these diseases. We use a variety of approaches, ranging from simple biochemical assays to complex transgenic organisms, in order to better understand the specific molecular and biochemical pathways that are involved in these diseases.
Universal Antigen Retrieval Compounds and Methods of Use. UHID2014-001. Eriksen J.L., Vollert, C.V, Gregory, S., Moree, W, Bark S., USPTO Serial No.: 14/530,142. Nonprovisonal patent application.
Žiburkus, J; Feng, G.; Eriksen, J.L.; Methods of Treating Neurological Diseases. University of Houston. USPTO 20150051166 A1.
Annapragada, A.; Eriksen J. L.; Tanifum, E.; Dasgupta, I.; Cook, S., inventors; Lipid Based Nanoparticles. United States Application 20120258044. October 11, 2012.
Hutton, M.L.; Baker, M. C.; Gass, J. M.; Rademakers, R.; Eriksen, J. L.; Pickering-Brown, S.M.; Mackenzie, I.R.A; Feldman, H.; Kumar-Singh, S.; Van Broeckhoven, C.; Cruts, M.; Cannon, A.D.; Detecting and Treating Dementia. US 8486635 B2, Jul 16, 2013.
Eriksen J. L.; Dickson, D. W.; Baker, M. W.; Rademakers, R.; Robinson, T., inventors; Methods and Materials for Detecting and Treating Dementia. United States Patent 8,486,635. Issued 07/16/2013.
Selective Inhibition of ABeta42 by NSAID and NSAID Analogs. Mayo Medical Ventures and Myriad Pharmaceuticals, Inc. October 2, 2003. Licensed Invention Certificate.
Selective Inhibition of ABeta42 by NSAID and NSAID Analogs. Chiesi Farmaceutici S.p.A. October 8, 2001. Sponsored Research Funding.
- 2007-2008 Smith Foundation Fellowship
- 2002-2004 John Douglas French Alzheimer’s Foundation Fellowship
- 2002 8th International Conference on Alzheimer's Disease and Related Disorders Travel Fellowship
- 1998-2000 NRSA Predoctoral Fellowship (NIAAA, National Institutes of Health)
- 1998-2000 Loyola University Dissertation Fellowship, Loyola University of Chicago
- 1994-1998 Graduate Student Science Fellowship, Loyola University of Chicago
- 1992 Hughes Undergraduate Grant in Biology
National Institutes of Health (NIA). Targeted nanoparticles for the detection and treatment of cerebral amyloid angiopathy (1R15AG039008-01). PI: Eriksen, J.L., 2011-2014
Cure Alzheimer’s Fund. "Peek-and-Treat Approach to Diagnosis, Treatment and Monitoring of Alzheimer’ Disease. Co-PIs: Eriksen, J.L., and Annapragada, A., 2010-2011.
Alliance for Nanohealth. Nanoparticle Based Molecular Imaging of Cerebral Amyloid Angiopathy, A Major Risk Factor for Stroke. 2009-2010.
Alzheimer's Association. Role of PGRN in Microglial Activity in Alzheimer’s Disease. 2008-2010.
National Institutes of Health. Suppression of Tauopathy by Lysosomal Activation (1R21NS057651-01), 2007-2009
California Table Grape Council. The role of grape phytonutrients on Alzheimer’s disease. 2006-2008.
John Douglas French Alzheimer's Foundation. JDFAF Fellowship. 2002-2004.
National Parkinson's Foundation. HSP70 and Synucleinopathy. 2004-2005.
National Institutes of Health (NIA). P50 AG 16574. DJ1, Ab, and tau metabolism. 2004-2005
- International Journal of Comprehensive Pharmacy, Editorial-Advisory Board Member
- International Journal of Biomedical Research and Analysis, Editorial Board
- Journal of Psychopharmacology, guest editor
- Current Enzyme Inhibition (Bentham Science), guest Editor
- Neural Regeneration Research, Editorial Board (appointed 2010)
- Frontiers in Neurodegenerative Diseases, Review Editor (appointed 2010)
- Journal of Drug Metabolism and Toxicology, Editorial Board (Appointed 2010)
- Acta Neuropathologica
- Alzheimer's Association/li>
- Environmental Health Research
- Italian Ministry of Health
- John Douglas French Alzheimer’s Foundation
- Journal of Alzheimer’s Disease
- Journal of Biotech Research
- Journal of Psychopharmacology
- Life Sciences
- Molecular Neurobiology
- Neuroscience Letters
- PLoS One
- Translational Neuroscience
- U.S. Civilian Research and Development Foundation (CRDF)
- Alzheimer's Association
- U.S. Civilian Research and Development Foundation (CRDF)
- John Douglas French Alzheimer’s Foundation
Sun, L. and Eriksen, JL. Recent Insights into the Involvement of Progranulin in Frontotemporal Dementia. Current Neuropharmacology. 2011 Dec;9(4):632-42.
Eriksen JL. The enigmatic roles of microglial versus neuronal progranulin in neurological disease. Acta Neuropathol. 2010 Jan;119(1):107-9.
C. Cook, J. Gass, J. Dunmore, J. Tong, J. Taylor, J. Eriksen, E. McGown, J. Lewis, J. Johnston, L. Petrucelli. Aging is not associated with proteasome dysfunction in UPS reporter mice. PLoS One. 2009 Jun 11;4(6):e5888.
R. Rademakers, J.L. Eriksen, M.C. Baker, T. Robinson, Z. Ahmed, S.J. Lincoln, N.J. Rutherford, R.J. Crook, N. Finch, D.A. Stroh, K.A. Josephs, B.F. Boeve, D.S. Knopman, R.C. Petersen, J.E. Parisi, R.J. Caselli, Z.K. Wszolek , R.J. Uitti, H. Feldman, M.L. Hutton , I.R. Mackenzie, N.R. Graff-Radford and D.W. Dickson. Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Human Molecular Genetics. 2008 Dec 1;17(23):3631-42. Doi: 10.1093/hmg/ddn257
T.L. Kukar, T.B. Ladd, M.A. Bann, P.C. Fraering, R. Narlawar, A. Welzel, R.W. Price, J.L. Eriksen, K. Jansen-West, B.A. Cottrell, C. Verbeeck, B. Schmidt, D. Walsh, M.S. Wolfe, A. Fauq, E.H. Koo, T.E. Golde. Substrate Targeting by γ-Secretase Modulators. 2008 Jun 12. Nature. 453 (7197):925-9.
J.L. Eriksen and I.R. Mackenzie. Progranulin: normal function and role in neurodegeneration. J. Neurochem. 2008 Jan;104(2):287-97.
S. Weggen*, M. Rogers, J.L. Eriksen*,**. NSAIDs: small molecules for prevention of Alzheimer’s disease or precursors for future drug development? Trends in Pharmacological Sciences. 2007. *Corresponding author; **Senior author. 2007 Oct. 2007 Oct;28(10):536-43.
T. Kukar, S. Prescott, J.L. Eriksen, V. Holloway, M.P. Murphy, E.H. Koo, T.E. Golde, M.M. Nicolle. Chronic administration of r-flurbiprofen attentuates cognitive learning impairments in transgenic APP mice. 2007. Biomed Central. 2007 Jul 24;8:54.
J.L. Eriksen and C. Janus. Plaques, Tangles and memory loss in mouse models of neurodegeneration. Behavior Genetics. 2007 Jan;37(1):79-100.
M. Baker, I.R. MacKenzie, S.M. Pickering-Brown, J. Gass, R. Rademakers, C. Lindholm, J. Snowden, J. Adamson, A.D. Sadovnick, S. Rollinson, A. Cannon, E. Dwosh, D. Neary, S. Melquist, A. Richardson, D. Dickson, Z. Berger, J. Eriksen, T. Robinson, C. Zehr, C.A. Dickey, R. Crook, E. McGowan, D. Mahn, B. Boeve, H. Feldman and M. Hutton. Mutations in Progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006 Aug 24;442(7105):916-9.
Z. Amtul, N. Kausar, C. Follmer, R.F. Rozmahel, Atta-Ur-Rahman, S.A. Kazmi, M.S. Shekhani, J.L. Eriksen, K.M. Khana and M.I. Choudharya. Cysteine based novel noncompetitive inhibitors of urease(s)—Distinctive inhibition susceptibility of microbial and plant ureases. Bioorganic & Medicinal Chemistry. 2006. 2006 Oct 1;14(19):6737-44.
S. Le Corre, H.W. Klafki, N. Plesnila, G. Hübinger, H. Sahagún, B. Monse, P. Seneci, J. Lewis, J. Eriksen, C. Zehr, M. Yue, E. McGowan, D.W. Dickson, M. Hutton, H.M. Roder. A novel inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proceedings of the National Academy of Sciences. 2006 June 20. 103 (5). 9673-9678,
E. McGowan, J. Eriksen, M. Hutton. A decade of modeling AD in transgenic mice. Trends in Genetics. 2006 May. 22 (5). 281-289.
E. McGowan, F. Pickford, L. Onstead, J. Eriksen, C. Yu, J. Kim, L .Skipper, M.P. Murphy, P. Das, K. Jansen, M. De Lucia, W-L Lin, G. Dolios, R. Wang, D.W. Dickson, M. Hutton, J. Hardy and T. Golde. Aβ42 is essential for Parenchymal and Vascular Amyloid Deposition in Mice. Neuron. 2005 July 21. 47. 191-199.
T. Kukar*, M.P. Murphy*, J.L. Eriksen*, SA Sagi*, S. Weggen, T.E. Smith, T. Ladd, M.A. Khan, J. Beard, M. Dodson, S. Merit, V.V. Ozols, P.Z. Anastasiadis, P. Das, A. Fauq, E.H. Koo and T.E. Golde. Diverse compounds mimic Alzheimer’s disease-causing mutations by augmenting Aβ42 production. Nature Medicine. 2005 May;11(5):545-50. *co-first author
J.L. Eriksen, S. Przedborski S, L. Petrucelli. Gene Dosage and Pathogenesis of Parkinson’s Disease. Trends in Molecular Medicine. 2005 March 5.
C.A. Dickey, J. Eriksen, A. Kamal, F. Burrows, M. Hutton, C.B. Eckman, L. Petrucelli. Development of a High Throughput Drug Screening Assay for the Detection of Decreases in Tau Expression Elicited by Novel HSP90 Inhibitors. Current Alzheimer’s Research. 2005 April 2. 231-8.
J.L. Eriksen, Z. Wszolek, L. Petrucelli. Molecular Pathogenesis of Parkinson’s Disease. Archives of Neurology. 2005 Mar. 353-7.
J.L. Eriksen and L. Petrucelli. Parkinson’s Disease – Molecular Mechanisms of Disease. Drug Discovery Today: Disease Mechanisms, 2005. 1 (4). 399-405.
J. Eriksen, M.P. Murphy, E. Head. “Chapter 7. Pharmacological models for preclinical testing: from mouse to dog to non-human primates.” In BACE: Lead Target for orchestrated therapy of Alzheimer’s disease. Editor John Varghese, Ph.D. John Wiley and Sons. 2009.
S. Weggen1, E. Czirr, S. Leuchtenberger, and J. Eriksen1,2. Non-steroidal anti-inflammatory drugs (NSAIDs) and derived A42-lowering molecules for treatment and prevention of Alzheimer’s disease (AD). Pharmacological Mechanisms in Alzheimer's Therapeutics. A. Claudio Cuello, ed. Springer Verlag. 2008. 1Corresponding author; 2Senior author.
J.L. Eriksen, C. Zehr, J. Lewis. Biologic Models of Neurodegenerative Disorders. Handbook of Clinical Neurology, 3rd Series. 2008. 89. 173-188. PMID: 18631742.
Jason Eriksen and Ananth Annapragada. Peek and Treat: Theranostic Particles for Alzheimer’s Disease. Invited presentation at the University of Texas Health Science Center at Houston, Department of Pathology and Laboratory Medicine. Jan. 14, 2011.
J. Eriksen. Nanoparticle Based Molecular Imaging of Cerebral amyloid Angiopathy, A Major Risk Factor for Stroke. Alliance for Nanohealth, The University of Texas Health Science Center at Houston. February 23, 2010.
J. Eriksen. Panel member, Town Hall Meeting, World Alzheimer’s Day, Rice University, Herring Hall. September 21, 2009.
J. Eriksen. Meeting of the German Society of Neuropathology and Neuroanatomy. The Role of Progranulin in Neurodegeneration. September 16-19, 2009. Düsseldorf, Germany. *Keynote speaker.
J. Eriksen. Progranulin and Alzheimer’s Disease. June 17, 2009. Bazelides Research Symposium. UT School of Public Health, Houston, TX. *Keynote speaker.
J. Eriksen. Official delegate, speaker. Bazelides Research Update. Let’s Talk Trash! Kaplan Theatre-Jewish Community Center. Houston, Texas. June 16, 2009.
M. Hutton, S. Melquist, M. Baker, C. Zehr, E. McGowan, D. Dickson, J. Eriksen, K. Ashe, D. Stephan, J. Lewis. The Tauopathies: From Genetics to Animal Models. The 10th Annual Conference on Alzheimer’s Disease and Related Disorders, 2006, Madrid, Spain.
J. Lewis, C. Zehr, C. Andorfer, J.L. Eriksen, J. Knight, M. Yue, T. Robinson, Z. Berger, A. Hanna, D.W. Dickson, C. Janus, E. McGowan, M. Hutton. Methods of Cell Death and Recovery in the rTg4510 and IP301L Inducible Mouse Models of Tauopathy. The 10th Annual Conference on Alzheimer’s Disease and Related Disorders, 2006, Madrid, Spain.
Ohia O, Pourzargham H, Kurz M.J., Lau Y-S, Eriksen, J. Effect of long-term exercise in a mouse model of Alzheimer’s disease. November 12-16, 2011. Society for Neuroscience, Washington, DC.
Hoshino, M. Helwig, C. Berridge, J. Eriksen, and I. Lindberg. Structure-function analysis of proSAAS as an Aβ1-42 anti-aggregant. Alzheimer’s Drug Discovery Foundation, September 26-27, 2011, Jersey City, New Jersey.
Tanifum E, Dasgupta I, Sun L, Ghaghada K, Annapragada A, Eriksen J. Development of Amyloid-Beta targeting nanoparticles for imaging and therapy. Society for Neuroscience, November 13-17 2010, San Diego, California.
Tanifum E, Dasgupta I, Sun L, Ghaghada K, Annapragada A, Eriksen J. Development of Amyloid-Beta targeting nanoparticles for imaging and therapy. Biomedical Engineering Society Annual Meeting, October 6-9 2010, Austin Texas.
Tanifum E, Dasgupta I, Sun L, Ghaghada K, Annapragada A, Eriksen J. Development of Amyloid-Beta targeting nanoparticles for imaging and therapy. Alzheimer’s Association Research Symposium, August 4, 2010, Houston, Texas.
E. Tanifum, I. Dasgupta, L. Sun, A. Annapragada, J. Eriksen. Nanoparticle Based Molecular Imaging of Cerebraamyloid Angiopathy, A Major Risk Factor for Stroke, Alliance for Nanohealth, February 23, 2010. The University of Texas Health Science Center at Houston.
J. Ness, M.J. Riemenschneider, S. Baches, J.L. Eriksen, C.U. Pietrzik, G. Reifenberger, S. Weggen. Progranulin (GRN), a protein mutated in frontotemporal dementia with ubiquitinpositive inclusions (FTLD-U), is abundantly expressed in human gliomas Authors: ICAD (2009).
G. E. Kisby, A. Olivas, T. Robinson, J. Eriksen, *P. S. Spencer; The cycad genotoxicant methylazoxymethanol (MAM) disrupts tau metabolism and increases tau phosphorylation during early brain development. Society for Neuroscience, 2008, Washington, D.C.
J.L. Eriksen, C. Zehr, C. Andorfer, M. Yue, J.Knight , T. Robinson, H. Melrose, E. McGowan, D.W. Dickson, M. Hutton, J. Lewis. Progranulin expression is enhanced with age and with the development of tauopathy in mice. Society for Neuroscience, 2007, San Diego, CA.
J.L. Eriksen, Z. Ahmed, W. Lin, A. Innes, T. Robinson, A. Nyborg, C. Zehr, E. McGowan, D.Dickson, M. Hutton. Light and electon Light and electron microscopic immunoreactivity of progranulin in Alzheimer’s Disease and mouse models of AD. Society for Neuroscience, 2007, San Diego, CA.
C. Zehr, Z. He, J.L. Eriksen, M. Yue, J.Knight , T. Robinson, H. Melrose, E. McGowan, D.W. Dickson, M. Hutton, J. Lewis. Deficits in axonal transport and their role in cell death and recovery in the rTg4510 tau mouse model. Society for Neuroscience, 2007, San Diego, CA.
J.L. Eriksen, C. Zehr, Z. Berger, T. Robinson, D. W. Dickson, J. Lewis, M. Hutton. Tau clearance through protein degradation pathways. Society for Neuroscience, 2006, Atlanta, GA.
R. Rademakers, M. Baker, I.R. Mackenzie, S.M. Pickering-Brown, J. Gass, C. Lindholm, J. Snowden, J. Adamson, A.D. Sadovnick, S. Rollinson, A. Cannon, E. Dwosh, D. Neary, S. Melquist, A. Richardson, D. Dickson, Z. Berger, J. Eriksen, T. Robinson, C. Zehr, C.A. Dickey, R. Crook, E. McGowan, D. Mann, B. Boeve, H. Feldman and M. Hutton. Mutations in Progranulin Cause Tau-Negative FTD. The 10th Annual Conference on Alzheimer’s Disease and Related Disorders, 2006, Madrid, Spain.
C. Zehr, W-L. Lin, A. Nylander, T. Robinson, J.L. Eriksen, D.W. Dickson, M. Hutton, J. Lewis. Apoptosis of Oligodendrocytes in an Inducible Model of Tauopathy. The 10th Annual Conference on Alzheimer’s Disease and Related Disorders, 2006, Madrid, Spain.
J.L. Eriksen, C. Zehr, Z. Berger, T. Robinson, J. Lewis, M. Hutton. Tau Clearance through Protein Degradation Pathways. Molecular Chaperones and the Heat Shock Response Meeting, 2006, Cold Spring Harbor, NY.
J.L. Eriksen. Selected NSAIDs Lower A42 Production. Centocor Corporation (Johnson & Johnson). Feb. 7, 2003. Malvern, PA.